The co‐seasonal application of anti‐IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children

Rolinck-Werninghaus, Claudia; Hamelmann, Eckard; Keil, Thomas; Kulig, Michael; Koetz, Karsten; Gerstner, Bettina; Kuehr, Joachim; Zielen, Stefan; Schauer, U.; Kamin, Wolfgang; Berg, Andrea von; Hammermann, J.; Weinkauf, Birgit; Weidinger, Gottfried; Stenglein, S.; Wahn, Ulrich

doi:10.1111/j.1398-9995.2004.00552.x

Cited by 113 publications

(111 citation statements)

References 22 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Especially in the first year of treatment, the clinical effects are limited. In a study by RolinckWerninghaus et al [47], treatment with SIT alone before the first grass pollen season was unable to reduce either symptom score or the use of rescue medication significantly in children when compared with the reference group of SIT with an irrelevant allergen.…”

Section: Discussionmentioning

confidence: 95%

Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children

Rosewich

Schulze

Eickmeier

et al. 2010

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummarySpecific immunotherapy (SIT) is a well-established and clinically effective treatment for allergic diseases. A pollen allergoid formulated with the T helper type 1 (Th1)-inducing adjuvant monophosphoryl lipid A (MPL) facilitates short-term SIT. Little is known about mechanisms of tolerance induction in this setting. In a prospective study, 34 patients allergic to grass pollen (25 male, nine female, median age 10·2 years) received a total of 44 SIT courses (20 in the first, 24 in the second) with MPL-adjuvanted pollen allergoids. Immunogenicity was measured by levels of specific immunoglobulin G (IgGgrass) and IgG4grass by antibody blocking properties on basophil activation, and by induction of CD4 + , CD25 + and forkhead box P3 (FoxP3 + ) regulatory T cells (Treg). Specific IgG and IgG4 levels increased only slightly in the first year of SIT. In the second year these changes reached significance (P < 0·0001). In keeping with these findings, we were able to show an increase of Treg cells and a decreased release of leukotrienes after the second year of treatment. In the first year of treatment we found little evidence for immunological changes. A significant antibody induction was seen only after the second course of SIT. Short-course immunotherapy with pollen allergoids formulated with the Th1-inducing adjuvant MPL needs at least two courses to establish tolerance.

show abstract

Section: Discussionmentioning

confidence: 95%

Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children

Rosewich

Schulze

Eickmeier

et al. 2010

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis (1744). The co-seasonal administration of omalizumab after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass-pollen allergic children (1745)(1746)(1747). This combination might prove useful for the treatment of allergic rhinitis, particularly for polysensitized patients.…”

Section: Anti-igementioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,867

1,761

View full text Add to dashboard Cite

“…Among these, omalizumab, a humanized monoclonal antibody that binds circulating IgE and prevents its attachment to high-affinity IgE receptors, is the most extensively studied agent approved for the treatment of severe uncontrolled asthma with perennial sensitizations. However, a growing number of reports indicate its effectiveness in seasonal and perennial AR in adults/adolescents [90][91][92][93][94] and children [95][96][97][98][99]. Targeting the early phase of the allergic cascade could prove a significant allergic march-preventing treatment.…”

Section: Other Interventionsmentioning

confidence: 99%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of 'united airways disease' or 'respiratory allergy', implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the 'atopic march'. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

show abstract

The co‐seasonal application of anti‐IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children

Abstract: Co-seasonal Omalizumab therapy showed considerable effects in children with seasonal allergic rhinitis. The combination of SIT plus Omalizumab was clinically superior to each treatment alone during the first year of observation.

Cited by 113 publications

References 22 publications

Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children

Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

Contact Info

Product

Resources

About